Condition: Type 1 Diabetes · Sponsor: Institut de Recherches Cliniques de Montreal
The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.
This description comes directly from the study's public registry record.
Valérie Boudreau, PhD · 514-987-5643 · valerie.boudreau@ircm.qc.ca
Corinne Suppere · 514-987-5597 · corinne.suppere@ircm.qc.ca
Always discuss trial participation with your own doctor first.
| Institut de recherches cliniques de Montréal | Montreal, Quebec, Canada | Recruiting |
| Montreal Clinical Research Institute | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06683391